7,471 Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Acquired by First Bank & Trust

First Bank & Trust purchased a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 7,471 shares of the company’s stock, valued at approximately $205,000.

Several other hedge funds have also made changes to their positions in the stock. Allspring Global Investments Holdings LLC lifted its holdings in shares of BridgeBio Pharma by 17.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 5,322 shares of the company’s stock worth $135,000 after purchasing an additional 801 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in BridgeBio Pharma by 21.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,801 shares of the company’s stock valued at $170,000 after acquiring an additional 1,214 shares in the last quarter. Advisors Asset Management Inc. raised its stake in BridgeBio Pharma by 56.1% during the 3rd quarter. Advisors Asset Management Inc. now owns 4,576 shares of the company’s stock valued at $117,000 after acquiring an additional 1,645 shares in the last quarter. CWM LLC raised its stake in BridgeBio Pharma by 132.9% during the 3rd quarter. CWM LLC now owns 3,442 shares of the company’s stock valued at $88,000 after acquiring an additional 1,964 shares in the last quarter. Finally, Values First Advisors Inc. bought a new stake in BridgeBio Pharma during the 3rd quarter valued at $57,000. Institutional investors own 99.85% of the company’s stock.

Insiders Place Their Bets

In other BridgeBio Pharma news, CFO Brian C. Stephenson sold 4,148 shares of the firm’s stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $36.16, for a total transaction of $149,991.68. Following the completion of the sale, the chief financial officer now directly owns 102,464 shares in the company, valued at approximately $3,705,098.24. This trade represents a 3.89 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Neil Kumar sold 326,932 shares of the firm’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $36.29, for a total value of $11,864,362.28. Following the sale, the chief executive officer now owns 5,371,515 shares of the company’s stock, valued at $194,932,279.35. The trade was a 5.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 3,496,239 shares of company stock worth $122,612,036. 24.66% of the stock is currently owned by company insiders.

BridgeBio Pharma Stock Up 1.4 %

NASDAQ:BBIO opened at $36.81 on Friday. BridgeBio Pharma, Inc. has a 1-year low of $21.62 and a 1-year high of $39.47. The firm has a market capitalization of $6.96 billion, a price-to-earnings ratio of -15.27 and a beta of 1.07. The stock has a fifty day simple moving average of $31.71 and a 200 day simple moving average of $27.85.

BridgeBio Pharma (NASDAQ:BBIO) last released its quarterly earnings results on Thursday, February 20th. The company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.22). Equities analysts predict that BridgeBio Pharma, Inc. will post -2.56 earnings per share for the current year.

Wall Street Analysts Forecast Growth

BBIO has been the topic of several recent analyst reports. Bank of America lifted their target price on BridgeBio Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, November 25th. Evercore ISI lifted their target price on BridgeBio Pharma from $45.00 to $50.00 and gave the company an “outperform” rating in a research note on Monday, December 23rd. Scotiabank lifted their price target on BridgeBio Pharma from $48.00 to $49.00 and gave the company a “sector outperform” rating in a research report on Wednesday, February 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $49.00 price target on shares of BridgeBio Pharma in a research report on Thursday, February 13th. One investment analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat, BridgeBio Pharma currently has a consensus rating of “Moderate Buy” and an average price target of $49.08.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.